Skip to main content

Assessing risks posed by the innate immune response modulating and the toxicity of the cellular product

29 Oct 2024
  • Can the  immune system  barrier for allogenic therapy and for vector based therapies be overcome ?
  • Can  universal cells  be produced safely ?
  • Can gene vectors be designed to escape the immune response ?
  • Will these be game changers in the field?
Industry Experts
Mahendra Rao, Chief Scientific Officer - Vita Therapeutics